Maintenance Treatment of Bipolar Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

February 28, 2009

Study Completion Date

April 30, 2009

Conditions
Bipolar DisorderDepression
Interventions
DRUG

Lamotrigine

If the participant is naive to LAM, LAM will be started at 25 mg every day for the first 2 weeks, then 50 mg per day for the next 2 weeks. The dose of LAM can be increased to 100 mg at week 5 and increased to maximum of 200 mg at week 6 based on symptoms, tolerability, and ratings of the rating scales. If the participant is already taking LAM, the dose will be increased to up to 200 mg using the same guide lines. Upon randomization the participant in the placebo comparator will have their dosage titrated to doubled since the potentiating effect of the Divalproex will no longer exist. It will remain at this dosage until the end of the study with the possibility of one adjustment for side effects.

DRUG

Divalproex (DIV) ER

If the participant is naive to DIV and if LAM was initiated before the start of treatment with DIV, DIV can be started at any point of time in the study provided the participant has been on LAM for at least 2 weeks. DIV will be started at 500 mg and titrated by increments of 500 mg every 3 to 4 days until a therapeutic blood level is attained up to 2500 mg.

DRUG

Placebo

During the randomized phase participants randomized to placebo comparator group will discontinue DIV and will start taking the placebo in the same fashion.

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT00183469 - Maintenance Treatment of Bipolar Depression | Biotech Hunter | Biotech Hunter